S13 Ep21: T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD
OncLive® On Air - En podkast av OncLive® On Air
Dr Nagasaka discusses the evolving use of T-DXd for HER2-mutated NSCLC in light of the emergence of investigational agents in this setting.
